Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 492Pancreatic Neoplasms 387Carcinoma, Hepatocellular 261Colonic Neoplasms 214Stomach Neoplasms 200Rectal Neoplasms 190Esophageal Neoplasms 157Neoplasms 139Carcinoma, Non-Small-Cell Lung 133Liver Neoplasms 129Neoplasm Metastasis 124Breast Neoplasms 102Cholangiocarcinoma 94Melanoma 85Ovarian Neoplasms 79Lung Neoplasms 72Squamous Cell Carcinoma of Head and Neck 57Carcinoma, Renal Cell 57Gastrointestinal Neoplasms 55Sarcoma 46Biliary Tract Neoplasms 39Prostatic Neoplasms 36Head and Neck Neoplasms 36Esophageal Squamous Cell Carcinoma 36Adenocarcinoma Of Esophagus 36Urinary Bladder Neoplasms 33Adenocarcinoma 33Uterine Cervical Neoplasms 31Triple Negative Breast Neoplasms 31Gastrointestinal Stromal Tumors 31

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × HER2 Positive Esophagogastric Cancer × Gastrointestinal × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡